Opko Health Inc (OPK) : The consensus on Opko Health Inc (OPK) based on 5 analyst recommendation on the company stock is 1.8, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Opko Health Inc (OPK) : The highest short term price target forecast on Opko Health Inc (OPK) is $20 and the lowest target price is $10. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $15.25 with a standard deviation of $4.27.
For the current week, the company shares have a recommendation consensus of Buy. Opko Health Inc (NYSE:OPK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.97 and $9.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.05, notching a gain of 1.31% for the day. The total traded volume was 2,157,292 . The stock had closed at $9.92 on the previous day.
In a related news, Frost Gamma Investments Trust, CEO of Opko Health, Inc., executed a transaction worth $98,800 on August 2, 2016. A total of 10,000 shares were purchased at an average price of $9.88. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.